Literature DB >> 25704428

Extended liver resections for intrahepatic cholangiocarcinoma: friend or foe?

Damien Bergeat1, Laurent Sulpice2, Michel Rayar3, Julien Edeline4, Aude Merdignac1, Bernard Meunier3, Eveline Boucher4, Karim Boudjema1.   

Abstract

BACKGROUND: In patients with intrahepatic cholangiocarcinoma (ICC), extended liver resections (ELRs) increase the rate of resectability. The aims of the present study were to evaluate the morbidity and oncologic outcomes of ELR compared with other liver resections (LR) for ICC.
METHODS: All LR for ICC that were performed in our center between January 1997 and September 2013 and conducted with curative intent were included in this retrospective analysis. ELRs were defined by resections of ≥5 liver segments. The factors that influenced the occurrence of major complications (Clavien ≥ 3) and overall survival (OS) were tested with univariate and multivariate analyses.
RESULTS: One hundred seven patients (82 men and 25 women) were resected, and 27 (25.3%) underwent ELRs. Compared with the LRs, the ELRs were performed in larger tumors (P = .003) and were significantly associated with more complex surgeries such as vascular (P < .001) or biliary reconstructions (P < .001). Multivariate analysis revealed that ELR was an independent risk factor for major complications (odds ratio [OR], 6.2; 95% CI, 2.11-19.62; P < .001). Compared with the other LRs, ELRs had no effects on OS or disease-free survival (P = .881 and P = .228, respectively). Perioperative blood transfusion (Hazard ratio (HR), 2.51; 95% CI, 1.49-4.23; P < .001), the presence of >1 nodule (HR, 3.17; 95% CI, 1.67-5.97; P < .001), and age ≥65 years (HR, 1.72; 95% CI, 1.03-2.86; P = .036) were independent prognostic factors for OS.
CONCLUSION: This study suggests that ELRs performed for large ICCs do not affect negatively oncologic outcomes, despite the increased risk of major complications.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25704428     DOI: 10.1016/j.surg.2014.11.011

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Prognostic Impact of Tumor Multinodularity in Intrahepatic Cholangiocarcinoma.

Authors:  Pietro Addeo; Issam Jedidi; Andrea Locicero; François Faitot; Constantin Oncioiu; Alina Onea; Philippe Bachellier
Journal:  J Gastrointest Surg       Date:  2018-11-26       Impact factor: 3.452

2.  Development and Validation of a Prognostic Score for Intrahepatic Cholangiocarcinoma.

Authors:  Mustafa Raoof; Sinziana Dumitra; Philip H G Ituarte; Laleh Melstrom; Susanne G Warner; Yuman Fong; Gagandeep Singh
Journal:  JAMA Surg       Date:  2017-05-17       Impact factor: 14.766

3.  Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system.

Authors:  Felix Hahn; Lukas Müller; Aline Mähringer-Kunz; Sebastian Schotten; Christoph Düber; Jan B Hinrichs; Sabine K Maschke; Peter R Galle; Fabian Bartsch; Hauke Lang; Arndt Weinmann; Roman Kloeckner
Journal:  PLoS One       Date:  2020-02-03       Impact factor: 3.240

Review 4.  Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Michele Ghidini; Antonio Ghidini; Giovanni Sgroi; Ivano Vavassori; Daniela Petrò; Mary Cabiddu; Alberto Aiolfi; Gianluca Bonitta; Alberto Zaniboni; Emanuele Rausa
Journal:  Surg Today       Date:  2021-01-03       Impact factor: 2.549

5.  Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma.

Authors:  Fabian Bartsch; Lisa-Katharina Heuft; Janine Baumgart; Maria Hoppe-Lotichius; Rabea Margies; Tiemo S Gerber; Friedrich Foerster; Arndt Weinmann; Beate K Straub; Jens Mittler; Stefan Heinrich; Hauke Lang
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

6.  Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study.

Authors:  Hongzhi Liu; Lianku Lin; Ziguo Lin; Yifan Chen; Qizhen Huang; Lei Ding; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Zhangjun Cheng; Yongyi Zeng
Journal:  BMC Cancer       Date:  2021-07-20       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.